This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           May 27, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

ACOG issues guidelines for hereditary cancer screening
Medscape (Free login required)
Risk assessment for hereditary cancer is the key to identifying patients and families who may be at increased risk of developing certain types of gynecologic cancer, according to a new committee opinion from the American College of Obstetrics and Gynecology (ACOG). The guidelines, published in the June issue of Obstetrics & Gynecology, recommend that clinicians refer patients to a genetic specialist if the initial screening suggests there might be a familial risk.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




OVARIAN CANCER


CHORUS results reported: Neoadjuvant chemotherapy associated with similar OS as primary surgery
HealthDay News via WebMD
Undergoing chemotherapy before surgery may help women battling advanced ovarian cancer, a new study published in The Lancet finds. The British study was led by Sean Kehoe, professor of gynecological cancer at the University of Birmingham, and included 550 patients. About half underwent the standard treatment of surgery followed by six cycles of chemotherapy, while the other half had three cycles of chemotherapy before their surgery.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Ovarian cancer biomarkers found
The San Diego Union-Tribune
UC San Diego researchers say they have found a potential new diagnostic for ovarian cancer, one of the most difficult cancers to detect and treat. The discovery of six isoforms of messenger RNA specific to ovarian cancer could also lead to new therapies, the researchers say in a study published in the Proceedings of the National Academy of Sciences.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


Risk factors for surgical complications in ovarian cancer
Cancer Network
A woman’s preoperative albumin level and the number of extended cytoreductive procedures performed were found to be the strongest predictors of perioperative morbidity when undergoing surgery for ovarian cancer, according to the results of a retrospective analysis published in Gynecologic Oncology. “Given that those women who require multiple extended procedures are at highest risk, these data suggest that alternative treatment strategies should be considered in women who may require extended cytoreductive surgery,” wrote Sonali Patankar, MD, of Columbia University College of Physicians and Surgeons in New York, and colleagues.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Study adds diabetes drug with anti-cancer effect to ovarian cancer treatment
Health Canal
Several recent studies have suggested that metformin, an established drug developed to treat patients with type II diabetes, may provide significant benefits, including increased survival, to patients being treated for advanced cancers. An analysis of combined results from these earlier studies found that metformin use was associated with a significant decrease in cancer risk, tumor burden and cancer mortality.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


MISSED AN ISSUE OF WOMEN'S CANCER NEWS?
Visit the SGO Women's Cancer News archive page.


  FEATURED COMPANIES
Advertisement
Register today!

Join ECG in Chicago on May 29th for an interactive symposium on BRCA Related Ovarian Cancer, Chaired by Thomas J. Herzog, MD.

Register today

Advertisement
Uncover Hereditary Cancer Risk for Your Patients
The average OB/GYN has 400 patients who meet criteria for further evaluation of hereditary cancer syndrome. Learn how to identify high-risk patients.


GENETICS


One-third of women with breast cancer desire genetic testing
Healio
Many women with nonmetastatic breast cancer expressed a strong desire for genetic testing, especially if they were younger or an ethnic minority, according to study results published in the Journal of Clinical Oncology. “With recent judicial opinions, direct-to-consumer marketing and celebrity reports, the public has become much more aware that genetic testing is available,” Reshma Jagsi, MD, DPhil, of the Center for Bioethics and Social Science in Medicine at the University of Michigan, said in a press release. “But genetic risk is complex. Even patients unlikely to have elevated genetic risk may still benefit from a discussion.”
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




ENDOMETRIAL CANCER


Patients with SLE before age 40 may have lower risk for breast, endometrial cancer
Healio
Patients with systemic lupus erythematosus (SLE) diagnosed before the age of 40 had a lower incidence of breast and ovarian cancers compared with the general population, according to research presented at the Canadian Rheumatology Association Annual Meeting. Data from 23 centers and 5,406 women diagnosed with SLE at a mean age of 26.8 years were collected. The data spanned 44,073 person-years with an average follow-up of 8 years per patient.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


BREAST CANCER


Link found between breast-cancer genes, prostate cancer
The Wall Street Journal
Mutations in two genes well known for increasing the risk of breast and ovarian cancer may also play an important role in advanced prostate cancer, researchers said, an unexpected discovery that could lead to new treatments for some men with the disease. Analysis of DNA from tumor tissue obtained from 150 men with late-stage prostate cancer revealed mutations in the BRCA1 or BRCA2 genes in about 15 percent of cases, according to a study published by the journal Cell. An additional 5 percent of the men had aberrations in genes with similar function.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE
 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

May 20, 2015
May 13, 2015
May 6, 2015
April 29, 2015






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063